Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...

and I have read estimates that somewhere between 13% to 30% of people over 80 with shingles will develop PHN. Now that she’s ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

PHN is operationally defined as pain that persists ... Immunocompromised patients might require longer periods of treatment. Treatment should be discontinued if both VZV DNA and anti-VZV antibody ...

and I have read estimates that somewhere between 13% to 30% of people over 80 with shingles will develop PHN. Now that she’s ...

In March 2023, my 94-year-old mother had a shingles episode on the right side of her neck, head, ear and (to a lesser degree) right cheek. The active blisters lasted about three weeks. Since then, she ...

The natural history of PHN is variable, but as a general rule ... I don’t know of any treatment that will improve the likelihood of her recovery. However, both the gabapentin she is on and ...